Phase 2 Study of DKN-01 in Colorectal Cancer
Ontology highlight
ABSTRACT: This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) [FOLFIRI/FOLFOX and bevacizumab] as second-line treatment of advanced CRC patients.
DISEASE(S): Colorectal Adenocarcinoma,Colorectal Cancer,Colorectal Cancer Metastatic,Colorectal Neoplasms,Colo-rectal Cancer
PROVIDER: 2743466 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA